鉴定TAP2作为人类癌症中的新型免疫标:综合生物信息学和实验方法的见解

Lufei Yang1,2,3,4, Jiawei Gui2,3,4,5, Yilei Sheng2,3,4,5

  • 1The 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.

概括

载体2 (TAP2) 与癌症预后不佳有关,并影响瘤微环境. 向TAP2可能会提高免疫治疗的有效性,并作为各种癌症的预后标记.